Neuropathic pain is a chronic disabling condition caused by different pathogenic mechanisms and seriously affects patient’s quality of life. Gabapentinoids, including pregabalin and gabapentin, have been recommended as one of the first-line drugs for the treatment of neuropathic pain. However, optimal dosing of these medications has been limited by adverse events such as dizziness, somnolence, peripheral edema and weight gain. Mirogabalin, a new generation ligand for the α2-δ subunits of voltage-gated calcium channels, provides long-lasting analgesic effects and a wider safety margin for adverse drug reactions due to the characteristic binding and dissociation kinetics for the α2δ-1 and α2δ-2 subunits. This article introduces the action mechanism, pharmacokinetics, clinical application, and reported clinical trials of mirogabalin for treating neuropathic pain.
목차
Abstract 서론 본론 약제 개요 작용기전 약제의 특성 적응증 용법 및 용량 동물 실험연구 임상사용 연구결과 부작용 및 주위사항 사용상의 주의사항 임상경험 사용보고 결론 참고문헌
Woong Mo Kim [ 김웅모 | Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Korea ]
Hyung Gon Lee [ 이형곤 | Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Korea ]
Corresponding Author